
1. microb pathog. 2013 feb;55:9-15. doi: 10.1016/j.micpath.2012.11.013. epub 2012
dec 13.

influenza respiratory syncytial virus (rsv) vaccines infants: safety,
immunogenicity, efficacy.

beeler ja(1), eichelberger mc.

author information: 
(1)division viral products, cber, ovrr, fda, united states.
judy.beeler@fda.hhs.gov

respiratory viral infections infants young children frequently cause
illness easily progress hospitalization death. are
currently licensed vaccines prevent respiratory viral disease children
younger 6 months, reflecting safety concerns difficulty inducing 
effective immune responses infants. review discusses vaccines have
been developed, currently developed, influenza and
respiratory syncytial virus, focus studies performed demonstrate
their safety efficacy, impact immunologic immaturity maternal 
antibodies infant response vaccines.

published elsevier ltd.

doi: 10.1016/j.micpath.2012.11.013 
pmcid: pmc7127028
pmid: 23247146  [indexed medline]

